Figure 2 indicate that the secondary endpoints were as follows: arrhythmia requiring treatment [7 (17.5%) vs. 14 (35.0%), P < 0.05] heart failure [0 vs. 1 (2.5%), P < 0.05], acute coronary event [4 (10.0%) vs. 8 (20.0%), P < 0.05], cTnI elevation [1 (2.5%) vs. 4 (10%), P < 0.01], and myocardial ischaemia [6 (15.0%) vs. 13 (32.5%), P < 0.01). The gene discussed is TNNI3; the disease is heart failure.